Jolt #3: Healthcare Caffeine, WoundSource Edition
by Colton Mason
Dermalink Technologies Inc. Announces Novel Biofilm Disruption Technology Platform for U.S. Wound Care Market
by Industry News
Pennington, NJ – March, 7 2018 – Dermalink Technologies Inc. (Dermalink) is pleased to announce the development of the first of its novel biofilm-disrupting products for the U.S. wound care market. The core ingredient, Lauroyl Arginine Ethylester (LAE), has been available in Europe for several years, where it has rapidly established itself as a proven anti-biofilm agent in the food and dental markets.
Designed to overcome the limitations and drawbacks of alternative products, Dermalink’s products employ LAE which has demonstrated multiple pathways of biofilm management including reduction of microbial adherence to tissue and dressing materials, disruption of intact Biofilms and anti-quorum forming activity. Disruption of established biofilms exposes microbes for destruction and elimination by the immune system or established antimicrobials and antiseptics. Reduction of microbial adhesion to wound tissue may result in the inability of planktonic organisms to congregate in sufficient numbers to establish viable biofilm colonies, and inclusion of LAE into surgical dressings prevents contamination of dressings extending their useful wear time up to seven days.
The first of a significant portfolio of LAE products include LAE hydrogel and wound cleanser/infusion solution providing direct support for biofilm-based advanced wound care, which is becoming the latest protocol for the management of hard to heal acute and chronic wounds, including venous stasis ulcers, diabetic extremity ulcers, and pressure ulcers.
About Dermalink Technologies, Inc
Dermalink Technologies, Inc. is a technology development company, working in the areas of anti-infectives, wound, and skin management. Dermalink has partnered with BioMed Laboratories LLC, Dallas (Texas), a leading OEM manufacturer in wound and skin care products, and ASN Associates, Inc., a leading research and new product development organization.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.